| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 2.2 | 1.8 |
| Profit before tax | -2.1 | -3.4 |
| Net income | -2.1 | -3.4 |
| EPS (diluted, $ a share) | $-2.44 | $-157.43 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +26.5% |
|---|---|
| Operating margin | -66.5% |
10-Q filed with the SEC, NASDAQ: IVF. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Invo Fertility, Inc.: key numbers
- Share price
- $2.18Close, Nov 17
- Market cap
- $2.6M
- Shares outstanding
- 1.19MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Invo Fertility, Inc.
All →Invo Fertility Financial Results
INVO Fertility reported Q3 2026 financial results featuring a 26% increase in total revenue to $2.2 million and a 28% growth in clinic-specific revenue. The company narrowed its net loss to $2.1 million and achieved its seventh consecutive quarter of positive clinic-level Adjusted EBITDA while significantly reducing liabilities by $5.5 million compared to year-end 2025.
- Term
- Q3 2026
Invo Fertility Reverse Stock Split
INVO Fertility, Inc. implemented a 1-for-4 reverse stock split of its issued, outstanding, and authorized common stock effective October 30, 2026. The split reduced the number of outstanding shares to approximately 1.2 million and adjusted the authorized share count to 62.5 million to maintain compliance with Nasdaq listing requirements. Trading commenced on a split-adjusted basis under the existing symbol 'IVF' with a new CUSIP number.